Evidence map›Paper›PMID 42010126›Full record

ArticleAnnals of hematology2026

Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes.

So Yeon Park, Hyeji Lee, Daehun Kwag, Gi June Min, Sung Soo Park, Jae-Ho Yoon, Sung-Eun Lee, Byung Sik Cho, Ki-Seong Eom, Hee-Je Kim and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

So Yeon Park *Department of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Hyeji Lee *College of Medicine, The Catholic University of Korea, Seoul, Korea.
Daehun KwagDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Gi June MinDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Sung Soo ParkDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Jae-Ho YoonDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Sung-Eun LeeDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Byung Sik ChoDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Ki-Seong EomDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Hee-Je KimDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Chang-Ki MinDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Seok-Goo ChoDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea.
Silvia ParkDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea. silvia.park@catholic.ac.kr.
Yoo-Jin KimDepartment of Hematology, Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul, 06591, Korea. yoojink@catholic.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myelodysplastic neoplasms (MDS). While matched sibling donors (MSD) have traditionally been preferred, the impact of donor type on transplant outcomes under anti-thymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis remains unclear. We analyzed 391 adult MDS patients receiving allo-HSCT with fludarabine–busulfan conditioning and ATG between 2009 and 2019. Donors included MSD (n = 155), unrelated donors (UD; n = 134), and haploidentical donors (HID; n = 102). At a median follow-up of 108 months, the 5-year overall survival (OS) and relapse-free survival (RFS) rates were 63.0% and 58.4%. While OS and non-relapse mortality (NRM) did not significantly differ by donor type, MSD recipients had a higher cumulative incidence of relapse compared to UD and HID recipients (34.3% vs. 16.4% and 16.8% at 5 years, p < 0.001), with a trend toward inferior RFS. In multivariate analysis, MSD was independently associated with increased relapse risk and a lower incidence of GVHD, which may reflect a reduced graft-versus-leukemia effect. In this single-center large cohort, MSD transplants were associated with higher relapse risk compared with alternative donors under ATG-based prophylaxis.

Indexed as

Antilymphocyte SerumHematopoietic Stem Cell TransplantationMyelodysplastic SyndromesTissue DonorsAdultAgedFemaleFollow-Up StudiesGraft vs Host DiseaseHumansMaleMiddle AgedRetrospective StudiesSiblingsSurvival RateTransplantation ConditioningAntilymphocyte SerumAnti-thymocyte globulinDonor selectionHematopoietic stem cell transplantationMyelodysplastic syndromes

Identifiers

PMID42010126
PMCPMC13095986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.